In all countries in the world as well Poland, there are no recommendations regarding testing of predictive factors qualifying non-small cell lung cancer (NSCLC) patients for molecularly targ...

 Abstract 9025 Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with advanced non-small cell lung cancer (NSCLC). Poster Board #351  Abstract 9064 Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve ALK fusion positive non-small cell lung cancer (ALK+ NSCLC). Poster Board #390  Abstract 9092 Atezolizumab...

Background: The tumor immune microenvironment influences evolution in non-small cell lung cancer (NSCLC). Yet, the prognostic value of programmed death-ligand 1 (PD-L1) epidermal growth factor receptor (EGFR)-mutant NSCLC remains controversial. Additionally, studies Filipinos with EGFR-mutant remain unexplored to this day.

background: to determine which radiotherapy parameters are associated with the tumor response of locally advanced non-small cell lung cancer (nsclc) patients undergoing concurrent chemoradiotherapy. materials and methods: thirty one patients with iiia/iiib nsclc underwent chemoradiotherapy with a median dose of 63 gy. on our actual treatments, we made radiotherapy planning to cover the planning...

High blood tumor mutational burden (bTMB) was significantly associated with progression-free survival (PFS) in non-small cell lung cancer (NSCLC) patients receiving atezolizumab. However, it failed to predict overall (OS). We hypothesized that ctDNA mass-adjusted bTMB (abTMB) might benefits NSCLC immune checkpoint inhibitors (ICIs) treatment.

Background: Recently, several clinical studies have evaluated the first-line use of immune checkpoint inhibitors (ICIs) combined with platinum-doublet chemotherapy in patients non-squamous non-small cell lung cancer (NSCLC), however, differences safety and efficacy between various types ICIs still require investigation. In this study, we NSCLC by meta-analysis indirect comparison.

The goal of radiation therapy for non-small cell lung cancer (NSCLC) is to improve the survival rate of patients without increasing treatment-related toxicity and to improve patients' quality of life. Several prospective randomized trials have demonstrated a survival advantage in combined modality treatment over radiotherapy or chemotherapy alone when a cisplatin-based chemotherapy regimen is u...

Introduction: Growth, proliferation, survival, and differentiation are the prominent characteristics of cells, which are affected by cancer. Epidermal growth factor receptor (EGFR) plays a pivotal role in the effective control of these features. Given the significance of EGFR signaling pathway in non-small cell lung cancer (NSCLC), EGFR expression is influential on these cell characteristics. I...

Immuno-oncology marked a therapeutic revolution in the treatment of cancer. Thanks to new strategy that aims awaken immune system fight cancer cells, there has been change clinical course advanced Non- Small Cell Lung Cancer (NSCLC). Our study aimed evaluate efficacy nivolumab monotherapy patients with stage IIIB/IV non-small cell lung beyond second line. The results showed progression-free sur...

Background: Nowadays, the influence of anesthesia management on prognosis cancer patients has been widely concerned. The goal this study is to assess association between anesthetic factors and with non-small cell lung (NSCLC) after surgery.